Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
Lintermans A, Laenen A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P. Lintermans A, et al. Among authors: christiaens mr. Ann Oncol. 2013 Feb;24(2):350-355. doi: 10.1093/annonc/mds290. Epub 2012 Oct 4. Ann Oncol. 2013. PMID: 23038762 Free article.
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P. Lintermans A, et al. Among authors: christiaens mr. Ann Oncol. 2011 Aug;22(8):1763-9. doi: 10.1093/annonc/mdq699. Epub 2011 Jan 27. Ann Oncol. 2011. PMID: 21273342 Free article.
Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up.
Haest K, Kumar A, Van Calster B, Leunen K, Smeets A, Amant F, Berteloot P, Wildiers H, Paridaens R, Van Limbergen E, Weltens C, Janssen H, Peeters S, Menten J, Vergote I, Morlion B, Verhaeghe J, Christiaens MR, Neven P. Haest K, et al. Among authors: christiaens mr. Ann Oncol. 2012 Jun;23(6):1449-54. doi: 10.1093/annonc/mdr478. Epub 2011 Oct 29. Ann Oncol. 2012. PMID: 22039079 Free article. Clinical Trial.
Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers.
Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Christiaens MR, Floris G, Moerman P, Van Limbergen E, Peeters S, Weltens C, Vergote I, Neven P. Brouckaert O, et al. Among authors: christiaens mr. Ann Oncol. 2012 Oct;23(10):2578-2584. doi: 10.1093/annonc/mds062. Epub 2012 Apr 6. Ann Oncol. 2012. PMID: 22492698 Free article.
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P. Lintermans A, et al. Among authors: christiaens mr. Breast Cancer Res Treat. 2014 Jul;146(1):109-16. doi: 10.1007/s10549-014-2986-7. Epub 2014 May 11. Breast Cancer Res Treat. 2014. PMID: 24816806
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
Wildiers H, Neven P, Christiaens MR, Squifflet P, Amant F, Weltens C, Smeets A, van Limbergen E, Debrock G, Renard V, Van Eenoo L, Wynendaele W, Paridaens R. Wildiers H, et al. Among authors: christiaens mr. Ann Oncol. 2011 Mar;22(3):588-594. doi: 10.1093/annonc/mdq406. Epub 2010 Aug 13. Ann Oncol. 2011. PMID: 20709813 Free article. Clinical Trial.
Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers.
Brouckaert O, Schoneveld A, Truyers C, Kellen E, Van Ongeval C, Vergote I, Moerman P, Floris G, Wildiers H, Christiaens MR, Van Limbergen E, Neven P; MBC Leuven, Belgium. Brouckaert O, et al. Among authors: christiaens mr. Ann Oncol. 2013 Jul;24(7):1847-1852. doi: 10.1093/annonc/mdt179. Epub 2013 May 16. Ann Oncol. 2013. PMID: 23680691 Free article.
Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
Neven P, Paridaens R, Amant F, Wildiers H, Berteloot P, Leunen K, Smeets A, Weltens C, van den Bogaert W, van Limbergen E, Christiaens MR, Vergote I. Neven P, et al. Among authors: christiaens mr. Int J Gynecol Cancer. 2006;16 Suppl 2:505-10. doi: 10.1111/j.1525-1438.2006.00682.x. Int J Gynecol Cancer. 2006. PMID: 17010059 Review. No abstract available.
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Dieudonné AS, Lambrechts D, Claes B, Vandorpe T, Wildiers H, Timmerman D, Billen J, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Weltens C, Van Limbergen E, Van den Bogaert W, Vergote I, Van Huffel S, Christiaens MR, Neven P. Dieudonné AS, et al. Among authors: christiaens mr. Breast Cancer Res Treat. 2009 Dec;118(3):531-8. doi: 10.1007/s10549-009-0463-5. Epub 2009 Jul 12. Breast Cancer Res Treat. 2009. PMID: 19597703
144 results